Novo Nordisk (NOVOB DC) is seeking to widen access to obesity treatments in Japan by targeting patients willing to pay out of pocket for GLP-1 drugs such as Wegovy, Bloomberg reports
Importance
Level 1
- The company will work with physicians and patients on self-funded treatment pathways, its Japan head Keisuke Kotani said.
#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#EUROPEAN EQUITIES